Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zioptan (tafluprost ophthalmic solution) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Latanoprostene bunod (LBN) demonstrated greater effectiveness in reducing intraocular pressure (IOP) compared to Unoprostone (-3.45 [95% CI: -4.77 to -2.12]) and several beta-blockers, including apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, and timolol. LBN showed numerical superiority over latanoprost (-0.70 [95% CI: -1.83 to 0.43]) and tafluprost (-0.41 [95% CI: -1.87 to 1.07]), and had similar efficacy to bimatoprost 0.01% (-0.02 [95% CI: -1.59 to 1.55]), but was slightly less effective than bimatoprost 0.03% (-0.17 [95% CI: -1.42 to 1.07]).
• The combination of prostaglandin analogues (PGs) with topical NSAIDs resulted in a significantly favorable IOP lowering effect in glaucoma patients (SMD: 1.3 and -0.03, 95% CI: 0.29 to 2.38 and -0.32 to 0.26, Z = 2.50 and 0.23, p = 0.013 and 0.820), indicating a potential benefit over PG monotherapy in this specific population.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.